Head-to-head comparison
Breeze Meds vs CoreAge Rx
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Charges nothing until a provider approves you, and now prints a starting price per product on its home page — $199 semaglutide, $399 tirzepatide — for the lowest dose.
From $199/mo sema · From $399/mo tirz · Verified August 2026
Marked down on: The public cards print only a floor per product — "Starting at $199" semaglutide, "Starting at $399" tirzepatide — and no term or dose ladder behind it
Desk Score
One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · Verified August 2026
Marked down on: The advertised $99/$149 per month is a 12-month plan paid in full ($1,188 / $1,788 up front); no month-to-month price is published
CoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for Breeze Meds. Breeze Meds still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Breeze Meds
78/100
C+
CoreAge Rx
94/100
A
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Breeze Meds | CoreAge Rx |
|---|---|---|
| Semaglutide | From $199/moFrom $199/mo (lowest dose — the card reads "Starting at $199"; higher doses may cost more; compounded injectable) | $99/mo12-month prepay$99/mo only as a 12-month plan paid in full ($1,188 in one charge); the lander says "starting at, based on a 12-month plan paid in full"; no month-to-month price is published; same price at every dose; compounded injectable |
| Tirzepatide | From $399/moFrom $399/mo (lowest dose — the card reads "Starting at $399"; higher doses may cost more; the $299 first-month rate seen inside the intake in July is no longer shown anywhere; compounded injectable) | $149/mo12-month prepay$149/mo only as a 12-month plan paid in full ($1,788 in one charge); no month-to-month price is published; same price at every dose; compounded injectable |
| Coverage | All 50 states | All 50 states |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | People who want an all-in nationwide option and accept that the published figures are lowest-dose floors, with the exact plan price inside the intake. | Anyone who can prepay a year and wants one dose-independent price with full nationwide reach. |
| Desk Score | 78/100C+ | 94/100A |
The verdict
Desk pick — CoreAge RxCoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for Breeze Meds. Breeze Meds still holds its ground where its strengths line up with yours.
Choose Breeze Meds if…
People who want an all-in nationwide option and accept that the published figures are lowest-dose floors, with the exact plan price inside the intake.
From $199/mo sema · From $399/mo tirz · All 50 states
Choose CoreAge Rx if…
Anyone who can prepay a year and wants one dose-independent price with full nationwide reach.
$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · All 50 states
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Breeze Meds · CoreAge Rx.
More head-to-heads
- Breeze Meds vs HealthRX
- CoreAge Rx vs Strut Health
- Breeze Meds vs RestorLife Med
- CoreAge Rx vs Ondra Health
- Breeze Meds vs Hims & Hers
- CoreAge Rx vs Sesame Care
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.